Establishment Labs Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ESTA research report →
Range $85 – $105
Price Chart
About the company
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand.
- CEO
- Fillipo Peter Caldini
- IPO
- 2018
- Employees
- 1,004
- HQ
- Austin, TX, US
Get TickerSpark's AI analysis on ESTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.06B
- P/E
- -55.39
- Fwd P/E
- 70.69
- PEG
- -0.68
- P/S
- 8.00
- P/B
- 138.16
- EV/EBITDA
- -218.65
- Div Yield
- 0.00%
- Gross Margin
- 70.18%
- Op Margin
- -6.57%
- Net Margin
- -14.56%
- ROE
- -203.65%
- ROIC
- -4.96%
Latest fiscal year · YoY change
- Revenue
- $211.08M+27.1%
- Gross Profit
- $146.31M+33.6%
- Op Income
- $-39,008,000
- Net Income
- $-51,064,000+39.6%
- EPS
- $-1.72+42.7%
- OCF Growth
- +13.0%
- FCF Growth
- +22.2%
- 52W High
- $97.59
- 52W Low
- $53.16
- 50D MA
- $65.72
- 200D MA
- $72.38
- Beta
- 1.00
- RSI (14)
- 55
- Avg Volume
- 413.18K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Establishment Labs delivered a strong Q3 with 33.9% revenue growth, first-ever positive free cash flow, and raised full-year guidance on U.S. momentum, minimally invasive adoption, and improving operating leverage.· October 29, 2026
- Q3 revenue rose to $72 million, up 33.9% year over year, with U.S. revenue up 119% to $26 million and OUS revenue up 9.7% to $46 million.
- Adjusted EBITDA increased to $6.4 million from $1.2 million a year ago, and adjusted EBITDA margin expanded to 8.9%.
- The company generated $7.7 million of operating cash flow and $5.1 million of free cash flow, its first quarter of positive free cash flow in company history.
- Management raised 2026 revenue guidance to more than $274 million and expects full-year adjusted gross margin around 70.7% and positive adjusted EBITDA.
- Minimally invasive revenue exceeded expectations; management now expects it to top $40 million for the full year, up from prior guidance of more than $35 million.
Q3 revenue was $72 million, up 33.9% year over year from $53.8 million. U.S. revenue increased 119% to $26 million, and revenue outside the U.S. increased 9.7% to $46 million. GAAP gross profit was $49.7 million and GAAP gross margin was 69.1% versus 70.1% in the prior-year quarter; excluding $1.3 million of restructuring-related inventory charges, adjusted gross margin was 70.8%, up 70 basis points year over year. GAAP operating expenses were $52.3 million versus $41.7 million a year ago; adjusted operating expenses were $49.6 million, or 68.8% of revenue. GAAP EBITDA was a loss of $0.9 million versus a loss of $2.2 million; adjusted EBITDA was $6.4 million versus $1.2 million, with margin of 8.9% versus 2.2%. Preliminary net loss was $10.7 million, or $0.35 per share, versus a loss of $11.1 million, or $0.38 per share. Operating cash flow was $7.7 million and free cash flow was $5.1 million. Cash and cash equivalents ended at $75.8 million. For 2026, management raised revenue guidance to more than $274 million from $269 million to $271 million previously, expects adjusted gross margin to be aligned with year-to-date performance of approximately 70.7%, kept adjusted operating expense guidance at $195 million to $200 million, and said the updated outlook supports positive adjusted EBITDA for the full year. Management also expects minimally invasive revenue to exceed $40 million for the full year and reiterated a 2027 revenue growth target of 25%.
Peter Caldini said the quarter showed broad-based momentum and category expansion through innovation, particularly in the U.S. and in minimally invasive products. He emphasized that the company is gaining share, increasing utilization within existing accounts, and building a more scalable model that can support growth into 2027. His tone was upbeat and confident, especially around the company’s first positive free cash flow quarter and the potential for reconstruction and other product launches.
Sandra Harris focused on the financial leverage showing through the model: adjusted gross margin was 70.8%, up 70 basis points year over year, and adjusted operating expenses fell to 68.8% of revenue from 77.6% last year. She highlighted the company’s first positive free cash flow quarter, with $7.7 million of operating cash flow and $5.1 million of free cash flow, and noted cash of $75.8 million at quarter-end. She also said the company gets more than $5 million in quarterly cash interest savings during the initial PIK period, and reaffirmed disciplined spending while maintaining investment in U.S. expansion and the innovation pipeline.
Analysts focused on three areas: the sustainability of OUS growth, the Q3 dip in minimally invasive revenue versus Q2, and how much room remains to raise utilization within existing U.S. accounts. Management said OUS markets were generally stable, with the main exception being the Middle East due to the ongoing conflict, and stressed that the direct markets delivered 16% growth for the quarter. On minimally invasive, management attributed the Q/Q decline to normal Q3 seasonality in Europe and reiterated the full-year expectation of more than $40 million. On utilization, management said the focus has shifted from account adds to increasing orders per account, aided by a larger sales force of 55 reps and targeted marketing, and said the current 43% Motiva utilization among users should continue to rise. Questions on reconstruction timing were met with cautious confidence: management said FDA review is progressing, timing is still uncertain, and approval could come by year-end or early next year.
The call showed strong momentum across the core business, with U.S. revenue more than doubling and OUS continuing to grow despite some regional weakness. Management also pointed to improving economics: positive free cash flow, expanding adjusted EBITDA margin, and a raised full-year revenue outlook. The company sees multiple growth levers still in front of it, including higher utilization in existing U.S. accounts, broader adoption of minimally invasive products, and possible reconstruction approval.
OUS growth still has regional sensitivity, with management calling out weaker Middle East demand tied to the ongoing conflict and noting variability in distributor order timing. Gross margin was helped by mix, but management said a higher-than-planned distributor mix lowered the percentage versus expectations, which could keep margins dependent on channel mix. Reconstruction is not yet approved, and management repeatedly noted that FDA timing is uncertain and that hospital VAC processes can take 3 to 6 months even after approval.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.6%
- Shares Outstanding
- 29.82M
- Float Shares
- 27.32M
of shares held by institutions
210 13F filers
Buy/sell ratio 5.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rtw Investments, LP | 2.67M | ▲ 10.00K |
| Jw Asset Management, LLC | 2.45M | ▼ 241.79K |
| Price T Rowe Associates Inc | 1.97M | ▲ 438.76K |
| Blackrock, Inc. | 1.58M | ▼ 4.27K |
| Brown Advisory Inc | 1.12M | ▼ 195.80K |
| Franklin Templeton Inc | 814.56K | ▲ 200.86K |
| Findell Capital Management LLC | 805.00K | ▼ 291.00K |
| Mudita Advisors Llp | 723.06K | 0 |
| William Blair Investment Management, LLC | 668.31K | ▼ 45.74K |
| Two Sigma Investments, LP | 657.84K | ▲ 209.41K |
| Tyro Capital Management LLC | 653.36K | ▲ 47.80K |
| Rice Hall James & Associates, LLC | 510.03K | ▼ 50.91K |
Held by 169 ETFs
Biggest fund positions in ESTA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Gillin Leslie | other | 262 |
| Sep 30, 26 | SCHUTTER EDWARD J | other | 253 |
| Sep 30, 26 | LEWIN NICHOLAS SHERIDAN | other | 389 |
| Sep 30, 26 | Slotkin Bryan | other | 253 |
| Sep 30, 26 | Custin Ann | other | 301 |
| Aug 20, 26 | Caldini Filippo | other | 682 |
| Apr 24, 26 | Chacon Quiros Juan Jose | other | 11,315 |
| Apr 24, 26 | LEWIN NICHOLAS SHERIDAN | other | 19,561 |
| Jun 24, 26 | Harris Taylor C. | other | 1,773 |
| Jun 24, 26 | Harris Taylor C. | other | 1,949 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ESTA coverage
Recent articles, reports, and earnings notes.
No research on ESTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ESTA report →Baron Discovery Fund Q3 2026 Portfolio Activity
seekingalpha.com · Nov 4
Establishment Labs Holdings Inc. (ESTA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Oct 29
What Establishment Labs (ESTA) Said on Its Q3 Earnings Call
marketbeat.com · Oct 29
Establishment Labs® Reports Third Quarter 2026 Financial Results
businesswire.com · Oct 29
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Should You Buy?
zacks.com · Oct 22
Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29
businesswire.com · Oct 19
Contrasting Establishment Labs (NASDAQ:ESTA) & OraSure Technologies (NASDAQ:OSUR)
defenseworld.net · Oct 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.